ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 737

The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease

Elizabeth Volkmann1, Donald Tashkin 2, Michael Roth 3, Ning Li 2, Grace Kim 2, Jonathan Goldin 2, Maureen Mayes 4, Julio Charles 5, Philip Clements 2, Daniel Furst 6, Dinesh Khanna 7, Robert Elashoff 2 and Shervin Assassi 4, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 3University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 5University of Texas, Houston, Houston, 6University of California, Los Angeles, CA, 7Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Genetic Biomarkers, interstitial lung disease, patient outcomes and immunosuppressants, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) affects the majority of patients with systemic sclerosis (SSc). The disease course of ILD varies among SSc patients and no reliable clinical or biological parameters consistently predict outcomes. We investigated whether the presence of a gain-of-function MUC5B promoter polymorphism, previously shown to be strongly associated with idiopathic pulmonary fibrosis and rheumatoid arthritis-related ILD predicted response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF) in SSc-ILD.

Methods: 142 patients in Scleroderma Lung Study (SLS) II (Tashkin et al. Lancet Resp Med 2016) were randomized to receive either MMF for 2 years or oral CYC for 1 year followed by 1 year of placebo. Presence of ground glass opacity was a requirement for enrollment. Genotyping of the MUC5B rs35705950 single nucleotide polymorphism was performed using TaqMan Genotyping Assaysin all patients with an available DNA sample. The forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLCO) were measured every 3 months. Quantitaive Lung fibrosis (QLF) and Quantitative ILD (QILD) scores for whole lung (WL) and zone of maximum involvement (ZM) were measured at baseline and 24 months. Linear regression models with the outcomes of change in radiographic fibrosis and ILD scores at 24 months were created to investigate the relationship between the presence of the MUC5B variant and SSc-ILD progression.

Results: Among 128 SLS II participants, 23 (18%) possessed at least one copy of the MUC5B rs35705950 minor allele. There were no significant differences in the baseline characteristics between SSc-ILD patients with and without this variant with respect to age, sex, %diffuse disease, disease duration, FVC, DLCO, radiographic extent of fibrosis, nor the presence of honeycombing on high resolution computed tomography. Similar to available data from the general population, this variant was rare among African Americans (4%) in our cohort. The presence of this MUC5B variant was not significantly associated with the change of QLF-ZM, QLF-WL, QILD-ZM, QILD-WL scores at 24 months, even after adjusting for baseline extent of fibrosis, treatment arm, and race (Table 1). In addition, using a joint model analysis with the covariates of FVC, treatment arm, race and a time trend, the presence of the MUC5B variant did not predict the course of the FVC%-predicted.

Conclusion: Among SSc-ILD patients with ground glass opacity on imaging who received treatment with CYC or MMF in a rigorously-conducted clinical trial, the presence of MUC5B rs35705950 minor allele did not predict ILD disease progression. Future studies are needed to further investigate how the presence of this variant affects outcomes in other SSc populations.


SLS II_MUC5B_ACR_Table 1


Disclosure: E. Volkmann, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Pfizer, 1, 4; D. Tashkin, None; M. Roth, Genentech/Roche, 2; N. Li, None; G. Kim, None; J. Goldin, None; M. Mayes, Boehringer Ingelheim, 5, 8, 9, Corbus, 9, Corbus Pharma, 9, Eicos, 9, Eicos Sciences, 9, Galapagos, 5, 9, GlaxoSmithKline, 9, Mitsubishi Tanabe Pharma, 5, Mitsubishi-Tanabe, 5, Reata Pharma, 9, Reata Pharmaceuticals, 9, Sanofi, 9; J. Charles, None; P. Clements, None; D. Furst, Actelion, 2, 5, Actelion Pharmaceuticals, 2, 5, Amgen, 2, 5, BMS, 2, 5, CME, 5, 8, Corbus, 2, 5, Galapagos, 2, 5, Galapogos Novartis, 5, GlaxoSmithKline, 2, GSK, 2, 5, NIH, 2, Novartis, 2, 5, Pfizer, 2, 5, Roche/Genentech, 2, 5, Sanofi, 2, 5; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5; R. Elashoff, None; S. Assassi, Bayer, 2, Boehringer Ingelheim, 2, 5, 8, Integrity Continuing Education, 8, 9, Medscape, 8, 9, Momenta, 2.

To cite this abstract in AMA style:

Volkmann E, Tashkin D, Roth M, Li N, Kim G, Goldin J, Mayes M, Charles J, Clements P, Furst D, Khanna D, Elashoff R, Assassi S. The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-muc5b-promoter-variant-does-not-predict-outcomes-in-systemic-sclerosis-related-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-muc5b-promoter-variant-does-not-predict-outcomes-in-systemic-sclerosis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology